Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
15 Apr 24
DEFA14A
Additional proxy soliciting materials
15 Apr 24
DEF 14A
Definitive proxy
15 Apr 24
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf Life
11 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
ADMA Biologics Announces CFO Transition
28 Feb 24
8-K
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28 Feb 24
8-K
Other Events
21 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
8 Jan 24
8-K
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
18 Dec 23
8-K
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient
12 Dec 23
8-K
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
16 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
ADMA Biologics Announces Third Quarter 2023 Financial Results and Provides Business Update
8 Nov 23
8-K
Departure of Directors or Certain Officers
2 Oct 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update
9 Aug 23
8-K
ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA
19 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
6 Jun 23
DEFA14A
Additional proxy soliciting materials
22 May 23
8-K
Other Events
22 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
ADMA Biologics Announces First Quarter 2023 Financial Results and Provides Business Update
10 May 23
8-K
ADMA Biologics Announces Amendment to Credit Agreement
2 May 23
ARS
2022 FY
Annual report to shareholders
13 Apr 23
DEFA14A
Additional proxy soliciting materials
13 Apr 23
DEF 14A
Definitive proxy
13 Apr 23
10-K
2022 FY
Annual report
23 Mar 23
8-K
ADMA Biologics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
23 Mar 23
8-K
Departure of Directors or Certain Officers
10 Mar 23
8-K
ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA
8 Feb 23
8-K
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial Guidance
17 Jan 23
8-K
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
9 Dec 22
424B5
Prospectus supplement for primary offering
7 Dec 22
8-K
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
7 Dec 22
8-K
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate
6 Dec 22
424B5
Prospectus supplement for primary offering
6 Dec 22
Latest ownership filings
4
Kaitlin M. Kestenberg-Messina
2 Apr 24
4
Adam S Grossman
2 Apr 24
3
Kaitlin M. Kestenberg-Messina
2 Apr 24
4
STEVE ELMS
19 Mar 24
4
STEVE ELMS
15 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
SC 13G/A
TEACHERS ADVISORS, LLC
11 Mar 24
SC 13G/A
TIAA CREF INVESTMENT MANAGEMENT LLC
11 Mar 24
SC 13G/A
Nuveen Asset Management, LLC
11 Mar 24
4
BRIAN LENZ
8 Mar 24
4
Adam S Grossman
8 Mar 24
4
Adam S Grossman
4 Mar 24
4
BRIAN LENZ
4 Mar 24
4
ALISON CECILY FINGER
28 Feb 24
4
Adam S Grossman
28 Feb 24
4
Jerrold B Grossman
28 Feb 24
4
YOUNG KWON
28 Feb 24
4
Lawrence P. Guiheen
28 Feb 24
4
Bryant Fong
28 Feb 24
4
STEVE ELMS
28 Feb 24
4
BRIAN LENZ
27 Feb 24
4
Adam S Grossman
27 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G
Nuveen Asset Management, LLC
14 Feb 24
SC 13G
TEACHERS ADVISORS, LLC
14 Feb 24
SC 13G
TIAA CREF INVESTMENT MANAGEMENT LLC
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
BRIAN LENZ
5 Jan 24
4
Adam S Grossman
5 Jan 24
4
Adam S Grossman
3 Oct 23
4
BRIAN LENZ
3 Oct 23
3
ALISON CECILY FINGER
2 Oct 23
4
Jerrold B Grossman
30 Aug 23
4
YOUNG KWON
24 Aug 23
4
Bryant Fong
23 Aug 23
144
Notice of proposed sale of securities
22 Aug 23
4
Adam S Grossman
18 Aug 23
144/A
Notice of proposed sale of securities (amended)
18 Aug 23
4
Adam S Grossman
17 Aug 23